Tech Company Financing Transactions
Prolium Bioscience Funding Round
RTW Investments participated in a $50 million Series A capital raise for Prolium Bioscience. The round was announced on 3/3/2026.
Transaction Overview
Company Name
Announced On
3/3/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
40 West 10th Avenue, 7th Floor
New York, NY 10014
USA
New York, NY 10014
USA
Phone
Undisclosed
Website
Email Address
Overview
Prolium is a clinical-stage biotechnology company focused on bringing breakthrough therapy to patients with autoimmune diseases. Established in 2025 and backed by RTW Investments in New York City, we are led by seasoned entrepreneurs and clinicians with deep experience in drug development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Requadt
Browse more venture capital transactions:
Prev: 3/3/2026: Vento Games venture capital transaction
Next: 3/3/2026: Fig Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs